1.Composed of a TP63 break-apart probe and staining solution, it performs in situ hybridization staining based on routine staining to provide auxiliary diagnostic information for physicians.
2.Used to detect the break-apart rearrangement status of the TP63 gene, which can occur in ALK-negative ALCL. The 2016 WHO classification introduced the subtype "ALK-negative ALCL (anaplastic large cell lymphoma)," where TP63 rearrangement accounts for approximately 8% of cases negative for ALK break-apart. This alteration is associated with a poor prognosis, with a 5-year survival rate of about 17%.